arrow
M

Monserrat Llaguno-Munive

instituto nacional de cancerologia
H指数:12
被引数:270

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Corrigendum to ‘Preclinical evaluation of several polymeric micelles identifies Soluplus®-docetaxel as the most effective candidate in multiple glioblastoma models’ [Journal of Controlled Release (2025) 381:113616]

勘误:‘在多种胶质母细胞瘤模型中,对多种聚合物胶束的体外表征评估发现Soluplus®-docetaxel是最有效的候选物’ [《控制释放杂志》(2025)381:113616]

2025-12-080
OAAI
Preclinical evaluation of several polymeric micelles identifies Soluplus®-docetaxel as the most effective candidate in multiple glioblastoma models

多种胶质母细胞瘤模型的临床前评估鉴定出Soluplus®-多西他赛为最有效的候选物。

2025-05-010
PRE
Preclinical Development of Magnetic Nanoparticles for Hyperthermia Treatment of Pancreatic Cancer

磁纳米粒子用于胰腺癌热疗治疗的临床前开发

2025-01-022
PRE
Scanning pulsed laser ablation in liquids: An alternative route to obtaining biocompatible YbFe nanoparticles as multiplatform contrast agents for combined MRI and CT imaging
2023-03-010
PRE
Intracellular Delivery of Anti-Kirsten Rat Sarcoma Antibodies Mediated by Polymeric Micelles Exerts Strong In Vitro and In Vivo Anti-Tumorigenic Activity in Kirsten Rat Sarcoma-Mutated Cancers
2023-02-166
PRE
Efficacy of targeted nanoliposomes in reducing globotriaosylceramide (Gb3) accumulation in mouse models of Fabry disease
2022-02-010
PRE
SFRP1 increases TMPRSS2-ERG expression promoting neoplastic features in prostate cancer in vitro and in vivo
2020-07-169
OAAI